Compare Hims and Hers Health Inc (HIMS) vs US Bancorp (USB) Price & Performance

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.

U.S. Bancorp (USB) trades at $56.81, up 1.14% today, but technical indicators are bearish with moving averages signaling a downtrend. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Fundamentals show strong profitability with a 27.61% net income margin and a modest P/E of 11.38. The company recently raised its dividend by 3.8% to $0.54 per share, reflecting confidence in its financial health.

The outlook is mixed: analyst consensus is bullish with a $69.94 price target, but near-term technical weakness and macroeconomic sensitivity pose risks. Upside potential hinges on continued earnings outperformance and stable interest rates, while downside risks include regulatory changes and economic volatility.